Published in Genome Biol on March 01, 2005
Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res (2009) 3.52
Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS One (2012) 1.18
Ganoderma lucidum polysaccharides in human monocytic leukemia cells: from gene expression to network construction. BMC Genomics (2007) 0.96
Immune system: a double-edged sword in cancer. Inflamm Res (2013) 0.95
PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother (2014) 0.80
Immunological network signatures of cancer progression and survival. BMC Med Genomics (2011) 0.78
Bayesian profiling of molecular signatures to predict event times. Theor Biol Med Model (2007) 0.77
Molecular portraits of human breast tumours. Nature (2000) 94.14
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
The concept of immunological surveillance. Prog Exp Tumor Res (1970) 4.76
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
Genome-wide views of cancer. N Engl J Med (2001) 3.07
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res (2003) 2.53
BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol (2004) 2.20
Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother (2004) 1.99
Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer (2004) 1.80
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A (2003) 1.56
Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma (2003) 1.33
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol (2004) 1.33
Natural mechanisms protecting against cancer. Immunol Lett (2003) 1.11
Molecular diagnosis of lymphoid malignancies by gene expression profiling. Curr Opin Hematol (2002) 1.10
DNA microarrays in breast cancer: the promise of personalised medicine. Lancet (2003) 1.05
Cancer vaccines: an old idea comes of age. Cancer Biol Ther (2003) 1.00
The immunology of colorectal cancer. Surg Oncol (2004) 0.83
Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes. Cancer Invest (2004) 0.83
Discovery and immunologic validation of new antigens for therapeutic cancer vaccines. Int Arch Allergy Immunol (2004) 0.82